B of A Securities analyst Koichi Mamegano upgrades Takeda Pharmaceutical (NYSE:TAK) from Neutral to Buy and announces $20 price target.
B of A Securities Upgrades Takeda Pharmaceutical to Buy, Announces $20 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.